Pemetrexed Versus Erlotinib in the Second-line Treatment of Patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene
Jazyk angličtina Země Řecko Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
26722080
PII: 36/1/447
Knihovny.cz E-zdroje
- Klíčová slova
- NSCLC, Pemetrexed, chemotherapy, erlotinib, second-line treatment, targeted treatment,
- MeSH
- erbB receptory genetika MeSH
- erlotinib terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory plic farmakoterapie patologie MeSH
- nemalobuněčný karcinom plic farmakoterapie patologie MeSH
- pemetrexed terapeutické užití MeSH
- senioři MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- erbB receptory MeSH
- erlotinib MeSH
- pemetrexed MeSH
BACKGROUND: Pemetrexed and erlotinib represent different agents commonly used for the second-line treatment of patients with advanced-stage non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: We analyzed data of 137 patients with advanced-stage non-squamous NSCLC treated with pemetrexed or erlotinib in the second line. All patients harbored a wild-type epidermal growth factor receptor gene. Genetic testing was performed using a combination of denaturing capillary electrophoresis and direct Sanger sequencing. RESULTS: overall response rate and disease control rate in patients treated with pemetrexed was 20.8% and 62.5% vs. 6.3% and 53.2% in patients treated with erlotinib (p=0.022; p=0.358). Median progression-free and overall survival in patients treated with pemetrexed was 1.6 and 11.3 months vs. 1.9 and 11.4 months in patients treated with erlotinib (p=0.470 and p=0.942, respectively). Erlotinib was associated with skin rash and diarrhea; pemetrexed was associated with hematological toxicity and fatigue. CONCLUSION: A similar efficacy and different, although well-tolerated, toxicity profile of both pemetrexed and erlotinib was shown.
Center for Applied Genomics of Solid Tumours Genomac Research Institute Prague Czech Republic
Institute of Biostatistics and Analysis Faculty of Medicine Masaryk University Brno Czech Republic
